Metropolitan Life Insurance CO Compass Therapeutics, Inc. Transaction History

Metropolitan Life Insurance CO

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$1.2 - $2.29 $964 - $1,841	804 Added 71.66%	1,926 $3,000
Q4 2023 Feb 14, 2024	SELL	$1.4 - $1.98 $5,675 - $8,026	-4,054 Reduced 78.32%	1,122 $1,000
Q2 2023 Aug 10, 2023	BUY	$2.64 - $3.48 $13,664 - $18,012	5,176 New	5,176 $16,000

91.9M

Ticker CMPX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 101,285,000
Market Cap $139M
Description
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascula...

Get notified when there are updates to the investment portfolio of Metropolitan Life Insurance CO, based on Form 13F filings with the SEC.

Stay updated on Metropolitan Life Insurance CO with notifications on news.